Zalicus Initiates the First of Two Phase 2a Studies with Z160, a First-in-Class, Oral, State-Dependent, Selective N-type Calcium Channel Blocker, for the Treatment of Chronic Neuropathic Pain (NASDAQ: ...
An exclusive out-licensing deal could be worth up to $475 million to Neuromed Pharmaceuticals Ltd., which entered an agreement with Merck & Co. Inc. on N-type calcium channel blockers for pain and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback